Kathleen P. Richton - 16 Jul 2026 Form 3 Insider Report for enGene Therapeutics Inc. (ENGN)

Reporting relationship: SVP, Finance and Treasurer
Issuer ticker: ENGN
Reported as of: 16 Jul 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 22 Jul 2026, 16:05:27 UTC
Source filing: View source filing
Reporting owner signature: /s/ Kathleen P. Richton

Key filing fact

Kathleen P. Richton filed Form 3 for enGene Therapeutics Inc. (ENGN) on 22 Jul 2026.

Key facts

This page summarizes Kathleen P. Richton's Form 3 filing for enGene Therapeutics Inc. (ENGN).
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 22 Jul 2026, 16:05.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002145406 Primary reporting owner

Richton Kathleen P.

Relationship: SVP, Finance and Treasurer
Address: C/O 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, QUEBEC, CANADA
Signature: /s/ Kathleen P. Richton
Signature date: 22 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENGN holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,900
Date: 16 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENGN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 45,000
Exercise price: $7.39
Footnotes: F2

ENGN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 13,900
Exercise price: $9.53
Footnotes: F3

ENGN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 105,000
Exercise price: $1.75
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Consists of 6,900 unvested restricted stock units (RSUs) granted to the Reporting Person on January 30, 2026 pursuant to the Issuer's Amended and Restated 2023 Incentive Equity Plan (the "Plan"), which are scheduled to vest annually in substantially equal amounts for four years, commencing January 15, 2027, subject to the Reporting Person's continued service. Each RSU represents a contingent right to receive one common share of the Issuer.

Footnote F2

Non-qualified stock option grant awarded as an inducement award outside of the Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vested at 25% on January 27, 2026, with the remaining portion to vest monthly in substantially equal amounts for the following 36 months, subject to the Reporting Person's continued service.

Footnote F3

This option vests monthly in substantially equal amounts for 48 months, commencing January 30, 2026, subject to the Reporting Person's continued service.

Footnote F4

This option vests monthly in substantially equal amounts for 48 months, commencing June 16, 2026, subject to the Reporting Person's continued service.

SEC remarks

Exhibit 24 - Power of Attorney